
Merck’s KEYTRUDA Plus Padcev Significantly Extends Survival in Bladder Cancer
New Combination Therapy Demonstrates 47% Reduction in Event-Free Survival Events Why is this a game-changer for bladder cancer treatment? Merck, a global leader in healthcare, has announced groundbreaking results from the Phase 3 KEYNOTE-B15 trial, which demonstrated that the combination…









